[{"id":"e43e3d0d-a928-4113-b0cb-1cb1cbe5fa52","acronym":"","url":"https://clinicaltrials.gov/study/NCT07044908","created_at":"2025-07-05T14:01:51.038Z","updated_at":"2025-07-05T14:01:51.038Z","phase":"Phase 1/2","brief_title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","source_id_and_acronym":"NCT07044908","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-07-01"},{"id":"f19011bc-a0f1-46bf-8979-e38379c2fbd2","acronym":"NEO-COMBATXL","url":"https://clinicaltrials.gov/study/NCT06902376","created_at":"2025-06-07T14:40:06.805Z","updated_at":"2025-06-07T14:40:06.805Z","phase":"Phase 1","brief_title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","source_id_and_acronym":"NCT06902376 - NEO-COMBATXL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/03/2025","start_date":" 06/03/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-06-04"},{"id":"53796a59-6a92-429e-a054-ab12ec9e66b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06855849","created_at":"2025-06-07T15:05:19.495Z","updated_at":"2025-06-07T15:05:19.495Z","phase":"Phase 2","brief_title":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.","source_id_and_acronym":"NCT06855849","lead_sponsor":"Yonsei University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-03-04"},{"id":"1a5d5c5e-2d0c-4820-8c6b-6f33f98d1419","acronym":"INSIGHT 2","url":"https://clinicaltrials.gov/study/NCT03940703","created_at":"2021-01-18T19:24:17.010Z","updated_at":"2025-02-25T13:52:54.712Z","phase":"Phase 2","brief_title":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","source_id_and_acronym":"NCT03940703 - INSIGHT 2","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET amplification","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tepmetko (tepotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 09/19/2019","start_date":" 09/19/2019","primary_txt":" Primary completion: 05/11/2023","primary_completion_date":" 05/11/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-20"},{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"b727510f-e4dd-45d1-a75b-a7fd6215444a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598244","created_at":"2021-01-18T17:41:26.385Z","updated_at":"2025-02-25T14:15:11.442Z","phase":"Phase 1","brief_title":"Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors","source_id_and_acronym":"NCT03598244","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"76c77ff7-c81e-43e4-ae4a-aaef8350e163","acronym":"COCOON","url":"https://clinicaltrials.gov/study/NCT06120140","created_at":"2023-11-07T16:14:24.835Z","updated_at":"2025-02-25T14:42:28.607Z","phase":"Phase 2","brief_title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","source_id_and_acronym":"NCT06120140 - COCOON","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) • minocycline"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 11/07/2025","primary_completion_date":" 11/07/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-14"},{"id":"ecd3b97e-f85f-4235-ac7a-4003f3339215","acronym":"NEOpredict-EGF","url":"https://clinicaltrials.gov/study/NCT06784791","created_at":"2025-02-25T14:44:13.644Z","updated_at":"2025-02-25T14:44:13.644Z","phase":"Phase 2","brief_title":"Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)","source_id_and_acronym":"NCT06784791 - NEOpredict-EGF","lead_sponsor":"University Hospital, Essen","biomarkers":" EGFR • CD8 • CD163 • CD4 • NCAM1 • CD68","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • CD8 • CD163 • CD4 • NCAM1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-14"},{"id":"13d717d6-af81-4d62-b82e-e808705b0f8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965090","created_at":"2021-07-16T13:53:19.792Z","updated_at":"2025-02-25T15:12:09.657Z","phase":"Phase 2","brief_title":"A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04965090","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-13"},{"id":"c2c0bdf4-79cd-4e7d-b1f6-9bf7bf2f7d00","acronym":"SAVOIR","url":"https://clinicaltrials.gov/study/NCT03091192","created_at":"2021-01-17T17:49:25.734Z","updated_at":"2025-02-25T15:10:33.304Z","phase":"Phase 3","brief_title":"Savolitinib vs. Sunitinib in MET-driven PRCC.","source_id_and_acronym":"NCT03091192 - SAVOIR","lead_sponsor":"AstraZeneca","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/25/2017","start_date":" 07/25/2017","primary_txt":" Primary completion: 08/18/2019","primary_completion_date":" 08/18/2019","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-13"},{"id":"70cd0c5d-7d88-425d-9c89-b461c30c15c1","acronym":"AMIGO-1","url":"https://clinicaltrials.gov/study/NCT05299125","created_at":"2022-03-28T12:52:54.230Z","updated_at":"2025-02-25T15:19:41.079Z","phase":"Phase 2","brief_title":"Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations","source_id_and_acronym":"NCT05299125 - AMIGO-1","lead_sponsor":"Latin American Cooperative Oncology Group","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-02-12"},{"id":"875dde5d-a068-44c0-a533-8d1880dcc9a8","acronym":"MARIPOSA","url":"https://clinicaltrials.gov/study/NCT04487080","created_at":"2021-01-18T21:32:24.291Z","updated_at":"2025-02-25T15:18:45.913Z","phase":"Phase 3","brief_title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04487080 - MARIPOSA","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1074","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 06/29/2027","study_completion_date":" 06/29/2027","last_update_posted":"2025-02-12"},{"id":"8b86d973-6a4a-4265-ab5b-f102925ec3cd","acronym":"PAPILLON","url":"https://clinicaltrials.gov/study/NCT04538664","created_at":"2021-01-18T21:43:09.446Z","updated_at":"2025-02-25T15:18:48.860Z","phase":"Phase 3","brief_title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","source_id_and_acronym":"NCT04538664 - PAPILLON","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 308","initiation":"Initiation: 10/13/2020","start_date":" 10/13/2020","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-12"},{"id":"5f3b5bbb-9aff-4571-a252-57e8a1171808","acronym":"CHRYSALIS-2","url":"https://clinicaltrials.gov/study/NCT04077463","created_at":"2021-01-18T19:58:05.927Z","updated_at":"2025-02-25T15:34:28.760Z","phase":"Phase 1","brief_title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04077463 - CHRYSALIS-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 02/03/2025","primary_completion_date":" 02/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2025-02-11"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2025-02-25T15:33:33.328Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-11"},{"id":"d34aa307-ae7e-44e1-9d9a-f7de8a535562","acronym":"PALOMA-2","url":"https://clinicaltrials.gov/study/NCT05498428","created_at":"2022-08-19T18:11:07.577Z","updated_at":"2025-02-25T15:19:56.526Z","phase":"Phase 2","brief_title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05498428 - PALOMA-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 08/05/2026","study_completion_date":" 08/05/2026","last_update_posted":"2025-02-11"},{"id":"242a6457-aef1-4b8b-890a-953bd32e515a","acronym":"SAVANNAH","url":"https://clinicaltrials.gov/study/NCT03778229","created_at":"2021-01-18T18:41:19.683Z","updated_at":"2025-02-25T15:34:16.664Z","phase":"Phase 2","brief_title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","source_id_and_acronym":"NCT03778229 - SAVANNAH","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 367","initiation":"Initiation: 01/09/2019","start_date":" 01/09/2019","primary_txt":" Primary completion: 08/23/2024","primary_completion_date":" 08/23/2024","study_txt":" Completion: 05/28/2025","study_completion_date":" 05/28/2025","last_update_posted":"2025-02-10"},{"id":"74af1789-bdc4-49be-8227-be00ab7f39a0","acronym":"PALOMA","url":"https://clinicaltrials.gov/study/NCT04606381","created_at":"2021-01-19T20:31:31.743Z","updated_at":"2025-02-25T15:34:47.299Z","phase":"Phase 1","brief_title":"A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies","source_id_and_acronym":"NCT04606381 - PALOMA","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" MET","pipe":" | ","alterations":" EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 07/11/2024","primary_completion_date":" 07/11/2024","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2025-02-10"},{"id":"f1064650-0259-4959-8f4b-9c77670f97c9","acronym":"OrigAMI-2","url":"https://clinicaltrials.gov/study/NCT06662786","created_at":"2025-02-25T15:45:58.168Z","updated_at":"2025-02-25T15:45:58.168Z","phase":"Phase 3","brief_title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","source_id_and_acronym":"NCT06662786 - OrigAMI-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/18/2024","start_date":" 10/18/2024","primary_txt":" Primary completion: 12/15/2028","primary_completion_date":" 12/15/2028","study_txt":" Completion: 12/15/2032","study_completion_date":" 12/15/2032","last_update_posted":"2025-02-10"},{"id":"1bd3b65f-3d27-4d52-a00c-7ebcb1b64c6b","acronym":"KUNPENG","url":"https://clinicaltrials.gov/study/NCT04258033","created_at":"2021-01-18T20:41:41.946Z","updated_at":"2025-02-25T16:37:45.457Z","phase":"Phase 2","brief_title":"A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)","source_id_and_acronym":"NCT04258033 - KUNPENG","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/17/2020","start_date":" 01/17/2020","primary_txt":" Primary completion: 05/14/2024","primary_completion_date":" 05/14/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"dab562b9-279d-4fe8-b2fc-7ee0c721ed02","acronym":"KUNPENG-2","url":"https://clinicaltrials.gov/study/NCT05989542","created_at":"2023-08-14T14:10:14.391Z","updated_at":"2025-02-25T16:40:06.600Z","phase":"Phase 3","brief_title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","source_id_and_acronym":"NCT05989542 - KUNPENG-2","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" EGFR • KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement","tags":["EGFR • KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"cb4879f1-5eee-438d-aef4-7efd2ba1fd90","acronym":"OrigAMI-3","url":"https://clinicaltrials.gov/study/NCT06750094","created_at":"2025-02-25T17:04:29.028Z","updated_at":"2025-02-25T17:04:29.028Z","phase":"Phase 3","brief_title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","source_id_and_acronym":"NCT06750094 - OrigAMI-3","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 12/12/2024","start_date":" 12/12/2024","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 04/13/2029","study_completion_date":" 04/13/2029","last_update_posted":"2025-02-03"}]